The therapeutic potential of resveratrol: a review of clinical trials
暂无分享,去创建一个
M. Holz | A. Y. Berman | Adi Y. Berman | Rachel A. Motechin | Maia Y. Wiesenfeld | Marina K. Holz | Adi Y Berman
[1] T. Walle,et al. HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS , 2004, Drug Metabolism and Disposition.
[2] A. Chabowski,et al. Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials. , 2017, Nutrition.
[3] J. Auwerx,et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. , 2011, Cell metabolism.
[4] P. Belmonte-de-Abreu,et al. Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors , 2016, Nutrients.
[5] A. Alayev,et al. Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer , 2017, Journal of cellular physiology.
[6] Y. Shukla,et al. Resveratrol and cellular mechanisms of cancer prevention , 2011, Annals of the New York Academy of Sciences.
[7] R. Gambino,et al. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. , 2013, Current medicinal chemistry.
[8] Yu Qin,et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[9] K. Magyara,et al. Cardioprotection by resveratrol : A human clinical trial in patients with stable coronary artery disease , 2012 .
[10] L. Howells,et al. Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice , 2015, Science Translational Medicine.
[11] K. Klein,et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] P. Farmer,et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 , 2002, British Journal of Cancer.
[13] M. Garcia-Conesa,et al. Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence , 2013, Current pharmaceutical design.
[14] M. Trevisan,et al. Elicitation and accumulation of stilbene phytoalexins in grapevine berries infected by Botrytis cinerea , 2015 .
[15] A. Hekmatdoost,et al. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. , 2014, Nutrition research.
[16] N. Barzilai,et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.
[17] Norman R. Farnsworth,et al. Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes , 1997, Science.
[18] G. Rosner,et al. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination , 2015, The Prostate.
[19] J. Pezzuto. Resveratrol as an Inhibitor of Carcinogenesis , 2008 .
[20] Raymond Scott Turner,et al. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease , 2017, Journal of Neuroinflammation.
[21] James B. Brewer,et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease , 2015, Neurology.
[22] P. Elliott,et al. Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases—Safety, Pharmacokinetics, and Pharmacodynamics , 2011, Cancer Prevention Research.
[23] W. V. McCarthy,et al. The re'lationship of resveratrol production to infection of grapevine leaves by Botrytis cinerea , 2016 .
[24] Sameer S. Kulkarni,et al. The molecular targets of resveratrol. , 2015, Biochimica et biophysica acta.
[25] N. Seeram,et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. , 2004, Anticancer research.
[26] A. Alayev,et al. The Combination of Rapamycin and Resveratrol Blocks Autophagy and Induces Apoptosis in Breast Cancer Cells , 2015, Journal of cellular biochemistry.
[27] Zhiwei Wang,et al. Cellular signaling perturbation by natural products. , 2009, Cellular signalling.
[28] A. Alayev,et al. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells , 2014, Cell cycle.
[29] J. K. Kundu,et al. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. , 2006, Carcinogenesis.
[30] S. Radhakrishnan,et al. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways , 2010, BMC Cancer.
[31] S. Hamilton-Dutoit,et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease , 2016, Scandinavian journal of gastroenterology.
[32] V. Feigin,et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 , 2014, The Lancet.
[33] P. Kopp. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? , 1998, European journal of endocrinology.
[34] Donald J L Jones,et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. , 2010, Cancer research.
[35] G. Rottinghaus,et al. Trans-Resveratrol Alters Mammary Promoter Hypermethylation in Women at Increased Risk for Breast Cancer , 2012, Nutrition and cancer.
[36] A. Gescher,et al. Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4′‐tetramethoxystilbene (DMU‐212) on adenoma development in the ApcMin+ mouse and cyclooxygenase‐2 in human‐derived colon cancer cells , 2005, International journal of cancer.
[37] Karen L Jones,et al. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. , 2016, The American journal of clinical nutrition.
[38] J. Crowell,et al. Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent , 2007, Cancer Epidemiology Biomarkers & Prevention.
[39] Y. Yun,et al. Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway. , 2010, Vascular pharmacology.
[40] C. Dolea,et al. World Health Organization , 1949, International Organization.
[41] W. Wu,et al. 3,3',4,5,5'-Pentahydroxy-trans-stilbene, a resveratrol derivative, induces apoptosis in colorectal carcinoma cells via oxidative stress. , 2010, European journal of pharmacology.
[42] D. Hougaard,et al. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4‐month randomised trial in middle‐aged men , 2015, The Prostate.
[43] The effects of different familial Alzheimer’s disease mutations on APP processing in vivo , 2017, Alzheimer's Research & Therapy.
[44] Y. Qian,et al. A combination of isolated phytochemicals and botanical extracts lowers diastolic blood pressure in a randomized controlled trial of hypertensive subjects , 2016, European Journal of Clinical Nutrition.
[45] P. Elliott,et al. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma , 2013, British journal of haematology.
[46] B. Sümegi,et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. , 2011, The British journal of nutrition.
[47] H. Hausenblas,et al. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis. , 2015, Molecular nutrition & food research.
[48] Q. Bai,et al. Resveratrol improves delayed r‐tPA treatment outcome by reducing MMPs , 2016, Acta neurologica Scandinavica.
[49] L. Motiwale,et al. Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. , 2011, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[50] Xiangyi Zheng,et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo , 2010, Cancer science.
[51] J. Bhatt,et al. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. , 2012, Nutrition research.
[52] A. Alayev,et al. Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation , 2015, Annals of the New York Academy of Sciences.
[53] Weigang Yuan,et al. Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials , 2016, PloS one.
[54] S. Renaud,et al. Wine, alcohol, platelets, and the French paradox for coronary heart disease , 1992, The Lancet.
[55] R. Mensink,et al. Resveratrol Does Not Influence Metabolic Risk Markers Related to Cardiovascular Health in Overweight and Slightly Obese Subjects: A Randomized, Placebo-Controlled Crossover Trial , 2015, PloS one.
[56] L. Mucke,et al. Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.
[57] N. Seiler,et al. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. , 2000, Cancer letters.
[58] A. Reiss,et al. Resveratrol in cholesterol metabolism and atherosclerosis. , 2012, Journal of medicinal food.
[59] S. Pervaiz. Resveratrol-from the Bottle to the Bedside? , 2001, Leukemia & lymphoma.
[60] J. Saver,et al. Improving reperfusion therapy for acute ischaemic stroke , 2011, Journal of thrombosis and haemostasis : JTH.
[61] T. Walle. Bioavailability of resveratrol , 2011, Annals of the New York Academy of Sciences.
[62] Hongwei Yao,et al. Regulation of SIRT1 in cellular functions: role of polyphenols. , 2010, Archives of biochemistry and biophysics.
[63] N. Møller,et al. High-Dose Resveratrol Supplementation in Obese Men An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition , 2013 .
[64] Alan D. Lopez,et al. The Global Burden of Disease Study , 2003 .
[65] J. Baur,et al. Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. , 2013, International journal of cardiology.
[66] Sanghyun Cho,et al. Cardiovascular Protective Effects and Clinical Applications of Resveratrol. , 2017, Journal of medicinal food.
[67] G. Pasinetti,et al. Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. , 2015, Biochimica et biophysica acta.
[68] J. K. Kundu,et al. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IκB kinase activity , 2006 .
[69] M. Garcia-Conesa,et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. , 2012, The American journal of cardiology.
[70] B. Bonavida,et al. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. , 2004, Molecular cancer therapeutics.
[71] A. Alayev,et al. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors. , 2015, American journal of respiratory cell and molecular biology.
[72] M. Garcia-Conesa,et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. , 2012, Molecular nutrition & food research.
[73] A. Alayev,et al. Phosphoproteomics Reveals Resveratrol-Dependent Inhibition of Akt/mTORC1/S6K1 Signaling , 2014, Journal of proteome research.